Medicare Part D's Effects on Elderly Patients' Drug Costs and Utilization

被引:0
|
作者
Ketcham, Jonathan D. [1 ]
Simon, Kosali I. [2 ]
机构
[1] Arizona State Univ, Sch Hlth Management & Policy, WP Carey Sch Business, Tempe, AZ 85287 USA
[2] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2008年 / 14卷 / 11期
关键词
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To analyze Medicare Part D's net effect on elderly patients' use of and out-of-pocket (OOP) costs for prescription drugs and to compare these with standardized results from prior studies. Study Design: Our dataset contains 1.4 billion prescriptions from Wolters Kluwer Health from December 2004 through December 2007 for patients whose age as of 2007 was more than 57 years. Methods: Days' supply per capita, OOP cost per day's supply, and number of individuals filling prescriptions were compared before and after January 2006 for those over age 66 years versus those age 58-64 years. Adjustment was made for under-reporting of pure cash prescriptions in the data. Results: Elderly patients' utilization in the first year of Part D increased compared with that of supply near-elderly patients by 8.1% for days and 4.8% for the number of individuals filling prescriptions, and their OOP costs declined by 172%. Although elderly patients' OOP costs in the second year were reduced an additional 5.8%, days' supply increased by only an additional 1.0%. Correcting for the under-reporting of pure cash prescriptions yielded effects of 8.1% and -3.5% for days' supply and -15.6% and -7.2% for COP costs in 2006 and 2007, respectively. A standardized comparison with previous estimates from Walgreens data showed that our utilization estimates were 2.6 times larger. Conclusion: Part D lowered elderly patients' OOP costs and increased utilization, primarily during the first year of the program. Magnitudes vary substantially across studies because of differences in data and methods.
引用
收藏
页码:SP14 / SP22
页数:9
相关论文
共 50 条
  • [41] Per-patient-per-month drug costs in medicare part D protected classes
    Mucha, Lisa
    Masia, Neal A.
    Axelsen, Kirsten J.
    PHARMACOECONOMICS, 2006, 24 (Suppl 3) : 79 - 84
  • [42] Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
    Zhao, Yang
    Kuo, Tzu-Chun
    Weir, Sharada
    Kramer, Marilyn S.
    Ash, Arlene S.
    BMC HEALTH SERVICES RESEARCH, 2008, 8 (1)
  • [43] THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT PREVIOUS DRUG COVERAGE
    Liu, X. Q.
    Walton, S. M.
    Crawford, S. Y.
    Pickard, A. S.
    VALUE IN HEALTH, 2009, 12 (03) : A170 - A170
  • [44] Drug utilization and costs of erythropoietic agents in elderly patients with chronic kidney disease
    Lefebvre, P.
    Duh, M. S.
    Laliberte, F.
    Mckenzie, R. S.
    Mody, S.
    Bookhart, B.
    Piech, C. T.
    VALUE IN HEALTH, 2007, 10 (03) : A106 - A107
  • [45] Utilization of Medicare Part D Among Transplant Recipients
    Chisholm-Burns, M.
    Spivey, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [46] The Effect of Medicare Part D on Parkinson's Disease Patients
    Tarrants, Marcy
    Shea, Terrence
    Denarie, Michel
    Castelli-Haley, Jane
    NEUROLOGY, 2010, 74 (09) : A58 - A59
  • [47] The Effect of Medicare Part D on Parkinson's Disease Patients
    Grubb, ElizaBeth
    Shea, Terrence
    Denarie, Michel F.
    Tarrants, Marcy L.
    NEUROLOGY, 2011, 76 (09) : A560 - A560
  • [48] The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
    Duggan, Mark
    Morton, Fiona Scott
    AMERICAN ECONOMIC REVIEW, 2010, 100 (01): : 590 - 607
  • [49] The effect of the medicare part D on Parkinson's disease patients
    Tarrants, M. L.
    Shea, T.
    Denarie, M.
    Castelli-Haley, J.
    MOVEMENT DISORDERS, 2010, 25 (07) : S430 - S430
  • [50] The effect of Medicare Part D on the utilization of essential drugs by seniors without prior drug coverage
    Schneeweiss, Sebastian
    Patrick, Amanda R.
    Pedan, Alex
    Varasteh, Laleh
    Levin, Raia
    Shrank, William
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S34 - S34